Bevacizumab, Carboplatin, Paclitaxel, and Pembrolizumab
About
Membership operator: AND
Therapies: 4
Therapies
Bevacizumab (tx:ncit:C2039)
Carboplatin (tx:ncit:C1282)
Paclitaxel (tx:ncit:C1411)
Pembrolizumab (tx:ncit:C106432)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy group.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| EMA (1) FDA (2) | PD-L1 (CPS) >= 1 | Cervical Adenocarcinoma | Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab | |
| FDA (2) | PD-L1 (CPS) >= 1 | Cervical Squamous Cell Carcinoma | Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab |